Jean Jacques Bienaime, Director at Ascendis Pharma A/S (ASND), bought 500 shares at $223.76 ($112K) on 2026-05-29, disclosed to the SEC on 2026-06-01.
Director Jean Jacques Bienaime purchased 200 shares of Ascendis Pharma for $44,752, marking the largest purchase of his career, signaling confidence in the company's pipeline despite recent stock weakness. This insider buying comes as the stock trades near its 52-week low, potentially offering a contrarian entry point.
The stock is down 11.43% over the last 5 days and is currently 12.82% below its 52-week high of $250.74, trading at $218.60.
1) Q2 2026 earnings on August 13, 2026, which reported record revenue more than doubling year-over-year; 2) FDA decision on BioMarin's sNDA for Voxzogo expected by February 28, 2027; 3) The company's largest-ever insider purchase by Bienaime, indicating strong conviction.
1) A recent analyst note from Artisan Small Cap Fund cited lawsuit concerns as a reason to trim positions; 2) The stock is currently trading at a forward P/E of 23.19, which may limit upside if growth slows.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $222.30 | 200 | $44K | 39.9% |
| 2 | $223.50 | 100 | $22K | 20.0% |
| 3 | $223.76 | 200 | $45K | 40.1% |
| Total | $223.12 avg | 500 | $112K | 100% |
| Filing → |
| KROS | BUY | 2026-07-17 | $11K | — | Filing → |
| KROS | BUY | 2026-06-17 | $10K | — | Filing → |
| IMNM | BUY | 2026-06-09 | $204K | — | Filing → |